Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 2, 2021
Grant Date -
N/A
app pub date -
Feb 12, 2019
filing date -
Mar 6, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (AAD) fusion protein for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, binds to human serum albumin (HSA) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. The AAD fusion protein can also be used as a component for detection and quantitative analysis of arginine in a testing kit for various samples including blood, food and analytical samples.
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 4 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | May 2, 2025 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | May 2, 2029 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | May 2, 2033 |